Regulatory Dossier Preparation for Pacific Island Pharma Exports

As we learned better how to offer APIs with formulated goods to the Pacific Island markets, we faced a challenge for which we couldn’t find a solution in the regulatory textbooks available to us.

This challenge was multifaceted. It included the six different countries that had six different requirements for a compliant dossier.

Also included was the need to generate European Zone II stability data, which likely would be insufficient due to the similar climates of the countries.

This guide aims to explain what we learned from our first query response to the Papua New Guinea Ministry of Health and the current Pacific submission protocol.

Introduction

The Pacific Island pharmaceutical market represents a $2.3 billion opportunity with 100% import dependency and no domestic manufacturing capacity.

The pharmaceutical markets of the Pacific Island region operate under conditions fundamentally different from Western regulatory markets.

All six countries- Papua New Guinea, Fiji, Solomon Islands, Vanuatu, Tonga, and Samoa- source cover most of their pharmaceutical needs through imports.

The combined population across these markets is approximately 12.5 million people.

The regional pharmaceutical import spend is growing rapidly, driven by rising chronic disease burden and maternal health programs funded by donors including UNICEF, the Asian Development Bank, and the Global Fund.

Why does regulatory dossier quality matter more in Pacific markets than anywhere else?

In European or North American markets, procurement decisions rest on price, product range, and supply reliability.

In Pacific Island countries, a robust regulatory dossier is the single entry barrier that separates suppliers who succeed from those who remain at the door.

India’s position as the primary pharmaceutical supplier to Pacific Island countries is built on WHO-GMP certification, CPP (Certificate of Pharmaceutical Product) issuance through CDSCO, and WHO-PQ (World Health Organization Prequalification) dominance.

Indian manufacturers hold 57% of all APIs^[1] on the WHO Prequalified Medicines list, a direct qualification pathway for donor-funded procurement programmes across the Pacific.

However, that qualification advantage is only valuable if the submission dossier is prepared to the specific regulatory expectations of each target market.

What you will learn in this guide:

The Pacific Island state regulatory frameworks are consistently changing.

Check with relevant national control bodies or a registered local agent for the most updated information.

This guide captures the state of affairs as of June 2026.

For the latest changes to requirements for the submission of a dossier, contact the appropriate Ministry of Health directly.

What’s Next?: Now that we’ve covered the landscape and opportunity, let’s examine what makes Pacific Island pharmaceutical markets uniquely attractive to Indian exporters.

Why Pacific Island Countries are attractive for Indian Exporters

Demand exists for inexpensive, WHO-certified suppliers, as 12.5 million residents of 6 island nations completely rely on imported pharmaceuticals.

The Pacific Island Pharmaceutical Demand Profile

The 6 primary markets^[2] are as follows, listed in descending order of population:

The following are the most needed essential medicines across the 6 target markets:

Benefits of Indian Suppliers in the Pacific

Three critical advantages exist for Indian pharma suppliers in the context of the Pacific:

WHO-GMP Certification via CDSCO: CDSCO is a WHO-recognized stringent regulator.

A CDSCO WHO-GMP certificate is reliable for Pacific health ministries, as they do not have independent lab testing.

WHO-PQ (Prequalified) API Portfolio: Of all the APIs on the WHO Prequalified Medicines Lists, 57% are Indian.

Easier pre-qualifications mean increased procurement for Pacific countries, with donor support from UNICEF, ADB, and Global Fund.

Cost Effectiveness vs. EU/US: Indian generic APIs and finished formulations are 30-50% cheaper than EU/US equivalents.

Procurement Channels and Dossier Entry Points

The three channels through which Pacific Islands procure pharmaceuticals each require a different dossier format.

These channels can be summarized as follows:

Procurement Channel	Entry Point	Typical Timeline	Dossier Type
Ministry of Health Direct Tender	National health authority (e.g., PSBB in PNG, Fiji Ministry of Health Pharmacy)	6-12 months (for a new product)	Full CTD or country-specific registration dossier
Regional Distributor via Australia/NZ	Sydney- or Auckland-based distributor with TGA or Medsafe registration that supplies Pacific Ministries of Health	2-4 months (distributor procurement)	Simplified dossier: CPP + WHO-GMP certificate + CoA
Donor-Funded Programs	Procurement divisions of UNICEF, ADB, or Global Fund, with the Pacific Islands health ministry as the end user	3-6 months (donor approval process)	WHO Prequalification (WHO-PQ) or approval/certification from a stringent regulatory authority (SRA)

Data Point: India-Pacific Pharmaceutical Trade Growth

In FY2024 (April 2023-March 2024), India’s pharmaceutical exports to Australia and the Pacific Islands increased by 21%.

Australia and New Zealand are the main transshipment points in the Pacific Islands pharmaceutical supply chain.

Indian suppliers who hold WHO-GMP certification AND TGA (Australia) or Medsafe (New Zealand) product registration have the best access to government procurement in the Pacific.

What’s Next?: Now that we understand the market attractiveness and Indian supplier advantages, let’s examine the specific regulatory landscape each Pacific country enforces.

Understanding The Regulatory Environment in Pacific Island Countries

In Pacific Island country regulatory frameworks, three documents are considered non-negotiable: WHO-GMP certification, a CPP (Certificate of Pharmaceutical Product), and ICH Q1A Zone IVb stability data^[3] in a tropical climate.

The Shared Foundation – CPP, WHO-GMP, and Zone IVb Stability

The Pacific Islands’ six markets are unified in their non-negotiable regulatory requirements for three documents:

WHO Certificate of Pharmaceutical Product (CPP): Issued by CDSCO (India), for every finished formulation being exported.

It attests to the compliance of the manufacturing and the assurance of the product’s quality.

WHO-GMP Certificate – Indicates the manufacturing facility has the WHO-GMPs and is entitled to manufacture the claimed product category.

ICH Q1A Zone IVb Stability: Stability of the product is claimed at the condition of (65% RH)^[4] with a temperature of (30°C ± 2°C) at the claimed shelf life, with accelerated stability testing at (75% RH) and (40°C ± 2°C).

Zone IVb is critical for all Pacific Island markets because all six countries exist in tropical or subtropical climates.

A submission presenting only Zone II (25°C/60% RH) stability data will trigger deficiency letters or outright rejection in Papua New Guinea, Fiji, and Solomon Islands.

Vanuatu, Tonga, and Samoa may accept a Zone II-only submission without an outright rejection but will consider it insufficient and may ask for Zone IVb data in order to grant approval.

Country-Wise Regulatory Requirements and Our Experience Tips

This table catalogues the unique regulatory pathway for each country, the dossier type, the estimated processing time and our professional knowledge for Pacific submissions between 2023 and 2025:

Country	Requirements	Dossier Type	Timeline	Key Insights
Papua New Guinea	CTD, CPP, GMP clearances. Includes Form 4 (Import Permit MCR 2002 Schedule 2).	Full CTD (CTD-based)	~12 months	Provide 12-month Zone IVb stability data.
Fiji	Noted approvals: CTD (Simplified), WHO-PQ, TGA, Medsafe, EMA, FDA.	Simplified CTD	2-8 months	WHO-PQ status can significantly reduce review time.
Solomon Islands	CPP, GMP, and Recognized Market Approval (RMA).	Abbreviated Dossier (RMA-supported)	3-9 months	Submit a complete dossier to avoid delays.
Vanuatu	CPP, WHO-GMP, CoA, Basic Product File.	Light Dossier (Basic Product File format)	1-4 months	Ensure CPP and GMP certificates are current and valid.
Tonga	CPP, WHO-GMP, CoA, Packaging Specifications, Stability Data.	Simplified CTD​	1-4 months​	CoA should reference recognized pharmacopeial standards (USP/BP/IP).
Samoa	CPP, WHO-GMP, CoA, Stability Data.	Simplified CTD	2-5 months	WHO-EML and WHO-PQ products are generally preferred.

The Solomon Islands, Vanuatu, Tonga, and Samoa have less developed systems and therefore allow shorter dossiers, although they are very particular about the currency and completeness of the documents.

In the smaller island states, just one missing document may bring the approval process to a standstill for several months.

What’s Next?: Now that the country-specific context has been outlined, let us analyze the form and structure of the Core Technical Document (CTD) for the Pacific.

CTD Format: How we Prepare Dossiers For Pacific Markets

The ICH Common Technical Document (CTD)^[5] is the flexible baseline for all Pacific submissions, full 5-Module format for advanced markets (PNG, Fiji), abbreviated to relevant modules for lighter-requirement markets (Vanuatu, Tonga, Samoa).

Our Baseline: ICH CTD Format Adapted for Pacific Market Requirements

The ICH Common Technical Document (CTD) format organised into 5 Modules is our baseline dossier structure for all export markets, including Pacific Island countries.

The primary advantage of CTD for Pacific submissions is adaptability: we present a complete CTD for markets requiring it (Papua New Guinea, Fiji) while stripping to relevant modules for lighter submissions (Vanuatu, Tonga, Samoa) without recreating documents from scratch.

This modular design means one internal dossier can power submissions across the full Pacific region by simply extracting country-specific module combinations.

Module 1 – Regional / Administrative Documents

Module 1 is the fastest section to prepare; all documents exist at the facility level.

What to include in Module 1:

The Most Common Module 1 Error: Submitting a CPP where the product name on the CPP does not exactly match the product name on the label and the Manufacturing Licence.

Papua New Guinea’s PSSB specifically flags this mismatch and returns submissions with administrative deficiency letters.

Module 2 – Quality / CMC (Most Critical for Pacific Markets)

Module 2 is where Pacific regulators scrutinise submissions most heavily.

Incomplete or poorly organized Module 2 submissions create unnecessary query burdens.

Manufacturing Process (3.2.S.2 for API / 3.2.P.3 for Finished Product):

Describe the validated manufacturing process: key steps, in-process controls, batch size ranges.

For Pacific submissions, regulators rarely query the manufacturing process in technical depth, but a complete description prevents deficiency letters.

Include process validation summary and change control history if available.

Impurity Control (ICH Q3A/Q3B Standards):

Specify known impurities, specified impurities, and unspecified impurities with acceptance limits per ICH Q3A and ICH Q3B.

For nitrosamine-containing drug classes (sartans, H2-receptor antagonists, metformin), include full ICH M7 nitrosamine risk assessment proactively, even if not specifically requested.

Pacific regulators increasingly flag this post-2020; including it unprompted demonstrates quality-forward positioning.

Stability Data (3.2.S.7 / 3.2.P.8): The Most Critical Sub-Section:

This is where Pacific submissions most often succeed or fail. Include BOTH Zone II (25°C/60% RH) AND Zone IVb (30°C/65% RH) data sets.

Clearly label each. Summarise in a comparison table:

Stability Parameter	6-Month (Zone II)	6-Month (Zone IVb)	12-Month (Zone IVb)	Acceptance Limit
Assay (% of label claim)	98.5%	97.8%	96.2%	90-110%
Related Substance A (%)	0.05%	0.08%	0.12%	≤ 0.10%
Water Content (Karl Fischer)	3.2%	3.8%	4.1%	≤ 5.0%
Microbial Limits (TAMC, CFU/mL)	<100 TAMC	<100 TAMC	<100 TAMC	≤ 1000 TAMC

Container Closure System (3.2.P.7):

Microbial Limits (3.2.P.5):

Data Point: Nitrosamine Risk Assessment Post-2020

WHO and stringent regulatory authorities (FDA, EMA, TGA) now require proactive nitrosamine risk assessments for APIs and finished products containing nitrosatable drug substances or manufactured using nitrite-containing reagents.

For Pacific submissions, including this assessment proactively-even if not formally requested-demonstrates a quality posture that reduces query probability significantly.

Module 3 – Quality Overall Summary (QOS) and Non-Clinical/Clinical Summaries

Quality Overall Summary (QOS):

For Pacific submissions, maintain a concise QOS: 15-25 pages maximum.

Reference Module 3 sections directly rather than repeating data; Pacific regulators read the QOS as an orientation document.

Must be clear and internally consistent with Module 3 sections.

Highlight Zone IVb stability data prominently; don’t bury it in dense technical sections.

Non-Clinical Summary (2.4) and Clinical Summary (2.5):

For established generic products on the WHO Essential Medicines List,^[6] Pacific regulators accept literature references in place of original clinical data.

Reference published pharmacopoeia monographs (BP, USP, IP) and WHO model formulary.

Pacific regulators rarely have the capacity to evaluate original clinical data; they rely on published standards.

Modules 4 & 5 – When Full Non-Clinical and Clinical Data Is Required

NOT Required For:

Required For:

Micro-Summary: We’ve now covered the complete CTD structure for Pacific submissions from administrative documents (Module 1) through quality and CMC sections (Module 2/3) to summary documents. The critical takeaway is that Pacific regulators require Zone IVb stability data prominently positioned, CPP-label-manufacturing licence consistency, and nitrosamine risk assessment proactively included. Country-specific dossier types vary (full CTD for PNG/Fiji vs. abbreviated dossiers for Vanuatu/Tonga/Samoa), but the underlying quality data remains the same. The next section walks you through the internal process we use to prepare these dossiers without errors.

Step-by-Step: Our Internal Dossier Preparation Process

A consistent preparatory process avoids cross-referencing problems, ensures completeness of Zone IVb data, and eliminates most of the causes of deficiency.

The preparation of internal files is broken down into seven clear stages.

These clear stages define related responsibilities and key outputs that are subject to verification.

This process has reduced our deficiency letter rate from 23% (2023) to 4% (2025).

Step	Action	Responsible Team	Key Output	Key Pitfall
1	Product & Gap Analysis	RA + QA	Regulatory gap list	Missing Zone IVb stability data can delay submission by 6-12 months.
2	Zone IVb Stability Studies	QC / Stability Lab	Stability data package	Submitting without sufficient stability data.
3	Module 3 (CMC) Compilation	QA + Manufacturing	Complete CMC dossier	Using only Zone II stability data.
4	Module 1 Documentation	RA	CPP, GMP, PIL, authorizations	Expired CPP or missing documents.
5	Internal Dossier Review	QA Manager + RA Head	Reviewed dossier	Product name mismatches across documents.
6	Submission Preparation	RA + Admin	Submitted dossier & receipt	Using the wrong submission format.
7	Query Management	RA + QA	Timely query responses	Inconsistent or incomplete responses.

Key Process Insight: The #1 failure point in Pacific submissions is missing or incomplete Zone IVb stability data at Step 2. A gap discovered at Step 5 means restarting the entire timeline.

Always confirm Zone IVb stability data existence and completeness before Step 1 is finalized.

What’s Next?: After analysing the preparation process thoroughly, it is time to pay attention to the challenges manufacturers faced and their solutions.

Common challenges we faced & How we overcame them

Real-world Pacific submission failures reveal predictable patterns and proven solutions.

Challenge 1: Zone IVb Stability Data Gap on Established Products

Issue: Several of our products had complete Zone II (European market) stability data but no Zone IVb data.

Pacific submission dates were approaching with no Zone IVb data in hand.

A full fresh stability study would take 12 months beyond our submission timeline.

Resolution: Using samples subjected to Zone IVb conditions of 30°C/65% RH, we began a retrospective stability study based on ICH Q1A(R2).

At the same time, we provided a commitment letter providing 12-month completion with 6-month Zone IVb real-time stability data.

The Fiji Ministry of Health approved this first submission.

Challenge 2: PNG PSSB Query on Impurity Specification

Issue: In the case of an unspecified impurity limit, PSSB issues a deficiency letter.

While 0.10% per ICH Q3A is the limit, PSSB asked for a justification for accepting the impurity at that level.

Resolution: A documented justification was provided referring to ICH Q3A and included rationale for the toxicological threshold of concern (TTC) and other literature for the specification.

This rationale is now provided in advance for all Pacific API submissions in Module 3.2.S.3.

Challenge 3: CPP Name Mismatch with Label

Issue: The International Non-proprietary Name (INN) was listed on the Certificate of Pharmaceutical Product (CPP) issued to us, whereas the commercial label was a mix of the brand name and INN.

PNG PSSB remarked on this as a product identity inconsistency, and the dossier was sent back for modifications.

Resolution: We sought an amendment to the CPP via the CDSCO SUGAM Portal^[7], so that the label, CPP, and the name would be consistent.

Processing took 6 weeks. We now verify CPP-label alignment as Step 0 (before any formal submission preparation).

Challenge 4: Varying Submission Format Expectations

Issue: Fiji’s Ministry of Health is known to have accepted ‘simplified CTD’ as a combination of Module 1 + 2 summaries + abridged Module 3.

This is in contrast to the Customs and Pharmacy Board of the Solomon Islands, where a CoA and CPP + GMP were directly requested (and were the only requirements).

Resolution: Our RA team draws up a country-specific submission format matrix (updated on an annual basis).

Prior to all submissions, we make sure to verify with the local agent to check that the requirements have not changed.

Regulatory timelines change; formats shift as staff turnover occurs in small island health ministries.

Challenge 5: Communication Timelines with Island Authorities

Issue: PNG PSSB and Solomon Islands would take 4 to 8 weeks to respond after multiple follow-up emails. The lag in response added uncertainty.

Resolution: We hired registered agents based in Port Moresby and Honiara to act as our representatives for regulatory correspondence.

Local agents have personal lines of communication with the regulatory staff and mitigate months-long communication delays to days, as well as provide instant feedback on the state of the correspondence.

Now that we have the knowledge of actual failures, and consider the invested time and hard work for our recent Pacific submissions, we can take a look at the successful practices.

Best Practices from our Manufaturing Experience

Six practices embedded in our current protocol have reduced deficiency letters to 4% and accelerated average approval timelines by 35%.

WHO-GMP and CPP are the non-negotiable foundation

Every Pacific submission begins with two documents current and correct: WHO-GMP certificate and CPP (Certificate of Pharmaceutical Product).

Our rule: renew the GMP certificate and CPP annually even if validity has not expired, to avoid last-minute renewal delays holding up a submission.

This practice costs USD 500-800 annually per product but eliminates the catastrophic scenario of discovering an expired GMP certificate 2 weeks before a submission deadline.

Leverage CDSCO approvals strategically:

Pacific regulators value India’s capacity in pharmaceutical regulations, and therefore they consider CDSCO-approved products with an Indian market presence as highly credible products.

We always include the CDSCO manufacturing licence in Module 1 even if not formally required by the receiving authority.

This signals to Pacific reviewers: “This product meets India’s domestic regulatory standards; it has a proven quality history.”

Zone IVb Stability as a Continuous Programme

We maintain Zone IVb stability samples on an ongoing basis for every product in our Pacific market portfolio.

This eliminates the most common Pacific submission timeline failure: waiting 6-12 months for stability data when a new market opportunity arises suddenly.

When a donor-funded program (UNICEF, ADB, Global Fund) issues a Pacific procurement tender unexpectedly, we can submit within 4 weeks instead of 12 months.

Consistency in Batch Documentation

Pacific health ministries audit batch consistency when they receive repeat shipments.

Our Certificates of Analysis (CoA), batch records, and specification sheets are formatted identically across all Pacific submissions.

Regulators who see inconsistent document formats question manufacturing consistency.

Standardized batch documentation also accelerates review: regulators recognize familiar formatting and spend less time decoding document structure.

Local Agent Investment Pays for Itself

The cost of a registered local agent in PNG ( nearly USD 2,000-5,000/year) is recovered on the first shipment that avoids a 3-month communication delay.

We view local agent fees as a procurement cost, not an overhead cost.

Local agents provide:

Build Relationships at the Product Registration Level, Not Just Procurement Level

A strong regulatory relationship with the Ministry of Health reviewer creates goodwill that accelerates future product submissions beyond the first.

In smaller island states (Tonga, Samoa, Vanuatu), the pharmacist who reviews your dossier is often the same person who handles all pharmaceutical registrations for that ministry.

Building trust with that individual through consistent, complete, professional submissions creates a collaborative relationship rather than an adversarial regulatory encounter.

Micro-Summary : We’ve covered the complete journey from regulatory environment understanding through country-specific requirements, CTD module preparation, internal process steps, real-world challenges with solutions, and best practices that drive consistent success. The pattern is clear: Zone IVb stability data, CPP-label-manufacturing consistency, local agent support, and proactive quality documentation are the four pillars of Pacific submission success.

Conclusion & Key Takeaways

Summary: Your Pacific Market Entry Strategy

A strong regulatory dossier is not just a compliance requirement for Pacific Island markets; it is the primary differentiator between Indian suppliers who build sustainable Pacific market relationships and those who make one submission, receive one query, and give up.

The six markets covered in this guide represent over 12.5 million people who depend entirely on imported medicines.

An Indian manufacturer who arrives with Zone IVb stability data, a current CPP, a WHO-GMP certificate, and a partner local agent is not competing against other Indian suppliers.

They are often the only structured, documentation-ready supplier in the room.

Three Core Insights to Remember

Call to Action

If you are preparing to export pharmaceutical APIs, finished formulations, or active ingredients to Pacific Island markets (Papua New Guinea, Fiji, Solomon Islands, Vanuatu, Tonga, Samoa) and need regulatory dossier guidance, verification of Zone IVb stability data, CPP strategy, WHO-GMP certification, or local agent partnership recommendations, contact our regulatory affairs team for a confidential consultation.

We help Indian pharmaceutical manufacturers navigate Pacific Island regulatory landscapes with proven dossier preparation protocols, CDSCO compliance support, and direct partnerships with registered local agents across PNG, Fiji, and Solomon Islands.

Frequently Asked Questions